Based on the populations studied in clinical trials to date, retatrutide has been investigated primarily in adults living with obesity defined as a body mass index (BMI) of 30 kg/m or above as well as in those who are overweight (BMI 27 kg/m or above) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidaemia
The Dallas Perspective In Dallas, many wellness clinics and weight loss centers now offer both GLP-1 injections and hormone therapy
With new research released since February, we are now at a point where the evidence for GLP-1s and addiction is stronger than it was for mRNA vaccines when Operation Warp Speed began, and there are far more lives at stake
Similarly, Stojsavljevi et al
Over 60% of the providers that have applied for certification have a focus on weight-loss medication, and of those, 98% offer compounded GLP-1 medications
The study suggests that tesofensine effectively reduces food intake and weight gain in obese rats
